نتائج البحث - Kathleen M. Darcy

تنقيح النتائج
  1. 1
    Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer

    Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer حسب Xijing He, Ahmet Arslan, Mark Pool, T-T Ho, Kathleen M. Darcy, John S. Coon, William T. Beck

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro

    Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro حسب Xijing He, Mark Pool, Kathleen M. Darcy, S B Lim, Nelly Auersperg, John S. Coon, William T. Beck

    منشور في 2007
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer

    Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer حسب Charlotte Marcus, G. Larry Maxwell, Kathleen M. Darcy, Chad A. Hamilton, William P. McGuire

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study

    A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study حسب D. Scott McMeekin, Michael W. Sill, Doris M. Benbrook, Kathleen M. Darcy, Deborah J. Stearns-Kurosawa, Lynne Eaton, S. Diane Yamada

    منشور في 2007
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells

    Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells حسب Pang-ning Teng, Nicholas W. Bateman, Kathleen M. Darcy, Chad A. Hamilton, G. Larry Maxwell, Christopher J. Bakkenist, Thomas P. Conrads

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

    Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving... حسب Gillian Thomas, Shamshad Ali, Frank Hoebers, Kathleen M. Darcy, William H. Rodgers, Malti Patel, O. Abulafia, Joseph A. Lucci, Adrian C. Begg

    منشور في 2007
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Relationship Between<i>ERCC1</i>Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer

    Relationship Between<i>ERCC1</i>Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin a... حسب Thomas C. Krivak, Kathleen M. Darcy, Chunqiao Tian, Deborah K. Armstrong, Bora Baysal, Holly H. Gallion, Christine B. Ambrosone, Julie A. DeLoia

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer

    High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer حسب Jennifer Veneris, Kathleen M. Darcy, Paulette Mhawech‐Fauceglia, Chunqiao Tian, Ernst Lengyel, Ricardo R. Lastra, Tanja Pejović, Suzanne D. Conzen, Gini F. Fleming

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Trends in Uterine Cancer Mortality in the United States

    Trends in Uterine Cancer Mortality in the United States حسب Sahana Somasegar, Aya Bashi, Susan M. Lang, Cheng-I Liao, C. A. Johnson, Kathleen M. Darcy, Chunqiao Tian, Daniel S. Kapp, John K. Chan

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study

    BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study حسب Jamie Lesnock, Kathleen M. Darcy, Chunqiao Tian, Julie A. DeLoia, Melissa M. Thrall, Chris Zahn, Deborah K. Armstrong, Michael J. Birrer, Thomas C. Krivak

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study

    Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study حسب Leslie M. Randall, Bradley J. Monk, Kathleen M. Darcy, Chunqiao Tian, Robert A. Burger, Shu‐Yuan Liao, William A. Peters, Richard J. Stock, John P. Fruehauf

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

    Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunoh... حسب Russell J. Schilder, Michael W. Sill, Xiaowei Chen, Kathleen M. Darcy, Steven DeCesare, George Lewandowski, Roger B. Lee, Cletus Arciero, Hong Wu, Andrew K. Godwin

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

    Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary periton... حسب Kian Behbakht, Michael W. Sill, Kathleen M. Darcy, Stephen C. Rubin, Robert S. Mannel, Steven Waggoner, Russell J. Schilder, Kathy Q. Cai, Andrew K. Godwin, R. Katherine Alpaugh

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

    Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study حسب Carol Aghajanian, Michael W. Sill, Kathleen M. Darcy, Benjamin E. Greer, D. Scott McMeekin, Peter G. Rose, Jacob Rotmensch, Mack N. Barnes, Parviz Hanjani, Kimberly K. Leslie

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study

    Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study حسب Shu‐Yuan Liao, Kathleen M. Darcy, Leslie M. Randall, Chunqiao Tian, Bradley J. Monk, Robert A. Burger, John P. Fruehauf, William A. Peters, Richard J. Stock, Eric J. Stanbridge

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

    Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study حسب Gini F. Fleming, Michael W. Sill, Kathleen M. Darcy, D. Scott McMeekin, J.T. Thigpen, Lisa Adler, Jonathan S. Berek, Julia Chapman, Paul DiSilvestro, Ira Horowitz, James V. Fiorica

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study

    Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a compl... حسب Jean Hurteau, Mark F. Brady, Kathleen M. Darcy, William P. McGuire, Pamela Edmonds, Michael L. Pearl, I. I. Ivanov, Krishnansu S. Tewari, Robert S. Mannel, Kristine Zanotti, Doris M. Benbrook

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study

    Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecolo... حسب Chunqiao Tian, Christine B. Ambrosone, Kathleen M. Darcy, Thomas C. Krivak, Deborah K. Armstrong, Michael A. Bookman, Warren Davis, Hua Zhao, Kirsten B. Moysich, Holly H. Gallion, Julie A. DeLoia

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    NUAK1 (ARK5) Is Associated with Poor Prognosis in Ovarian Cancer

    NUAK1 (ARK5) Is Associated with Poor Prognosis in Ovarian Cancer حسب Neil T. Phippen, Nicholas W. Bateman, Guisong Wang, Kelly A. Conrads, Wei Ao, Pang-ning Teng, Tracy Litzi, Julie Oliver, G. Larry Maxwell, Chad A. Hamilton, Kathleen M. Darcy, Thomas P. Conrads

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study

    A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study حسب Kimberly K. Leslie, Michael W. Sill, Edgar Fischer, Kathleen M. Darcy, Robert S. Mannel, Krishnansu S. Tewari, Parviz Hanjani, Jason A. Wilken, Andre T. Baron, Andrew K. Godwin, Russell J. Schilder, Meenakshi Singh, Nita J. Maihle

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: